Alexion Pharmaceuticals Inc. (ALXN) PT Set at $211.00 by Leerink Swann


The firm presently has a "buy" rating on the biopharmaceutical company's stock. Leerink Swann's price objective points to a potential upside of 65.89% from the stock's current price.



from Biotech News